113 related articles for article (PubMed ID: 6358210)
1. Evidence that activation of platelets and endothelium by thrombin involves distinct sites of interaction. Studies with the dysthrombin, Thrombin Quick I.
Henriksen RA; Brotherton AF
J Biol Chem; 1983 Nov; 258(22):13717-21. PubMed ID: 6358210
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the catalytic defect in the dysthrombin, Thrombin Quick.
Henriksen RA; Owen WG
J Biol Chem; 1987 Apr; 262(10):4664-9. PubMed ID: 3558361
[TBL] [Abstract][Full Text] [Related]
3. Identification of the primary structural defect in the dysthrombin thrombin Quick I: substitution of cysteine for arginine-382.
Henriksen RA; Mann KG
Biochemistry; 1988 Dec; 27(26):9160-5. PubMed ID: 3242619
[TBL] [Abstract][Full Text] [Related]
4. The thrombin high-affinity binding site on platelets is a negative regulator of thrombin-induced platelet activation. Structure-function studies using two mutant thrombins, Quick I and Quick II.
Leong L; Henriksen RA; Kermode JC; Rittenhouse SE; Tracy PB
Biochemistry; 1992 Mar; 31(9):2567-76. PubMed ID: 1547239
[TBL] [Abstract][Full Text] [Related]
5. Interaction of thrombin and platelets with the vascular endothelium.
Hoak JC; Czervionke RL; Fry GL; Smith JB
Fed Proc; 1980 Jul; 39(9):2606-9. PubMed ID: 6995153
[TBL] [Abstract][Full Text] [Related]
6. Relationship between cyclic AMP and thromboxane formation in platelet-endothelial cell interactions.
Lagarde M; Felisi O; Boukhchache D; Sicard B; Dechavanne M
Thromb Res; 1984 Jul; 35(2):141-7. PubMed ID: 6089369
[TBL] [Abstract][Full Text] [Related]
7. Thrombin-induced endothelium-dependent inhibition and direct activation of platelet-vessel wall interaction. Role of prostacyclin, nitric oxide, and thromboxane A2.
Yang Z; Arnet U; Bauer E; von Segesser L; Siebenmann R; Turina M; Lüscher TF
Circulation; 1994 May; 89(5):2266-72. PubMed ID: 8181152
[TBL] [Abstract][Full Text] [Related]
8. Prostacyclin inhibits mobilisation of fibrinogen-binding sites on human ADP- and thrombin-treated platelets.
Hawiger J; Parkinson S; Timmons S
Nature; 1980 Jan; 283(5743):195-7. PubMed ID: 6985716
[TBL] [Abstract][Full Text] [Related]
9. Identification of a congenital dysthrombin, thrombin Quick.
Henriksen RA; Owen WG; Nesheim ME; Mann KG
J Clin Invest; 1980 Nov; 66(5):934-40. PubMed ID: 6776145
[TBL] [Abstract][Full Text] [Related]
10. Halysin, an antiplatelet Arg-Gly-Asp-containing snake venom peptide, as fibrinogen receptor antagonist.
Huang TF; Liu CZ; Ouyang CH; Teng CM
Biochem Pharmacol; 1991 Aug; 42(6):1209-19. PubMed ID: 1888330
[TBL] [Abstract][Full Text] [Related]
11. The fibrinogen-derived peptide (RGDS) prevents proteolytic degradation of protein kinase C in platelets by inhibiting platelet aggregation.
Krishnamurthi S; Dickens TA; Patel Y; Wheeler-Jones CP; Kakkar VV
Biochem Biophys Res Commun; 1989 Sep; 163(3):1256-64. PubMed ID: 2783136
[TBL] [Abstract][Full Text] [Related]
12. Trigramin. A low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb-IIIa complex.
Huang TF; Holt JC; Lukasiewicz H; Niewiarowski S
J Biol Chem; 1987 Nov; 262(33):16157-63. PubMed ID: 3680247
[TBL] [Abstract][Full Text] [Related]
13. Association of fibrinogen with human platelets pretreated with chymotrypsin or aggregated with ADP or thrombin: an immunocytochemical study.
Suzuki H; Kinlough-Rathbone RL; Packham MA; Yamazaki H; Mustard JF
Br J Exp Pathol; 1989 Aug; 70(4):479-88. PubMed ID: 2765399
[TBL] [Abstract][Full Text] [Related]
14. Human platelet activation is inhibited by the occupancy of glycoprotein IIb/IIIa receptor.
Padoin E; Alexandre A; Cavallini L; Polverino de Laureto P; Rao GH; Doni MG
Arch Biochem Biophys; 1996 Sep; 333(2):407-13. PubMed ID: 8809080
[TBL] [Abstract][Full Text] [Related]
15. Thrombocytin, a serine protease from Bothrops atrox venom. 2. Interaction with platelets and plasma-clotting factors.
Niewiarowski S; Kirby EP; Brudzynski TM; Stocker K
Biochemistry; 1979 Aug; 18(16):3570-7. PubMed ID: 476069
[TBL] [Abstract][Full Text] [Related]
16. The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets.
Gartner TK; Bennett JS
J Biol Chem; 1985 Oct; 260(22):11891-4. PubMed ID: 2995350
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a potent platelet aggregation inhibitor from Agkistrodon rhodostoma snake venom.
Huang TF; Wu YJ; Ouyang C
Biochim Biophys Acta; 1987 Sep; 925(3):248-57. PubMed ID: 3620499
[TBL] [Abstract][Full Text] [Related]
18. Substitution of valine for glycine-558 in the congenital dysthrombin thrombin Quick II alters primary substrate specificity.
Henriksen RA; Mann KG
Biochemistry; 1989 Mar; 28(5):2078-82. PubMed ID: 2719946
[TBL] [Abstract][Full Text] [Related]
19. Thrombin interaction with human platelets. Potentiation of thrombin-induced aggregation and release by inactivated thrombin.
Phillips DR
Thromb Diath Haemorrh; 1974 Sep; 32(1):207-15. PubMed ID: 4454040
[TBL] [Abstract][Full Text] [Related]
20. Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib.
Soslau G; Class R; Morgan DA; Foster C; Lord ST; Marchese P; Ruggeri ZM
J Biol Chem; 2001 Jun; 276(24):21173-83. PubMed ID: 11283012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
